PDL BioPharma to Present at Oppenheimer & Co. 20th Annual Healthcare
Conference on November 4, 2009
INCLINE VILLAGE, Nev., Oct. 27 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc.
(PDL) (Nasdaq: PDLI) today announced that John P. McLaughlin, the company's
president and chief executive officer, will present at the Oppenheimer 20th
Annual Healthcare Conference in New York City on Wednesday, November 4, 2009
at 9:40 a.m. Eastern Time
To access the live and subsequently archived webcast of the conference call,
go to the company's website at http://www.pdl.com and click "Investors."
Please connect to the website at least 15 minutes prior to the call to allow
for any software download that may be necessary. A replay will be available at
www.pdl.com starting approximately three hours after completion of the
webcast.
About PDL BioPharma, Inc.
PDL BioPharma pioneered the humanization of monoclonal antibodies and, by
doing so, enabled the discovery of a new generation of targeted treatments for
cancer and immunologic diseases. PDL is focused on maximizing the value of its
antibody humanization patents and related assets. The company receives
royalties on sales of a number of humanized antibody products marketed today
and also may receive royalty payments on additional humanized antibody
products launched before patent expiry in late 2014. For more information,
please visit www.pdl.com.
NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of
PDL BioPharma, Inc.
SOURCE PDL BioPharma, Inc.
Cris Larson of PDL BioPharma, Inc., +1-775-832-8505, Cris.Larson@pdl.com; or
Danielle Bertrand of WeissComm Partners, +1-415-946-1056,
dbertrand@wcpglobal.com, for PDL BioPharma, Inc.
